Veronica Cervati
Overview
Explore the profile of Veronica Cervati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
45
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leonetti A, Cervati V, Minari R, Scarlattei M, Verze M, Peroni M, et al.
Clin Lung Cancer
. 2024 Aug;
25(8):e436-e445.e9.
PMID: 39198088
Objectives: Despite the outstanding results achieved by osimertinib for the treatment of advanced EGFR-mutated NSCLC, the development of resistance is almost inevitable. While molecular mechanism responsible for osimertinib resistance are...
2.
Gasparro D, Scarlattei M, Silini E, Migliari S, Baldari G, Cervati V, et al.
Diagnostics (Basel)
. 2023 Oct;
13(19).
PMID: 37835825
In oligo-metastatic renal cell carcinoma (RCC), neither computed tomography (CT) nor bone scan is sensitive enough to detect small tumor deposits hampering early treatment and potential cure. Prostate-specific membrane antigen...
3.
Evangelista L, Bianchi A, Annovazzi A, Sciuto R, Di Traglia S, Bauckneht M, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765835
Aim: To examine the role of [18F]FDG PET/CT for assessing response to immunotherapy in patients with some solid tumors. Methods: Data recorded in a multicenter ( = 17), retrospective database...
4.
Durmo R, Filice A, Fioroni F, Cervati V, Finocchiaro D, Coruzzi C, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158862
Peptide receptor radionuclide therapy (PRRT) is an effective therapeutic option in patients with metastatic neuroendocrine tumor (NET). However, PRRT fails in about 15-30% of cases. Identification of biomarkers predicting the...
5.
Zanoni L, Mosconi C, Cervati V, Diegoli M, Monteduro F, Golfieri R, et al.
Eur J Nucl Med Mol Imaging
. 2020 May;
47(8):2038-2039.
PMID: 32430579
No abstract available.
6.
Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, et al.
J Urol
. 2019 Sep;
202(6):1181.
PMID: 31524577
No abstract available.
7.
Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, et al.
J Urol
. 2019 Jun;
202(6):1174-1181.
PMID: 31233369
Purpose: Prostate specific antigen persistence after radical prostatectomy is associated with adverse outcomes in patients with prostate cancer. We sought to define regions at risk for residual disease as well...
8.
Polverari G, Ceci F, Calderoni L, Cervati V, Farolfi A, Castellucci P, et al.
Clin Genitourin Cancer
. 2018 Dec;
17(2):154-156.
PMID: 30587404
No abstract available.
9.
Calderoni L, Matei Deliu V, Farolfi A, Lambertini A, Renne G, Lorenzini D, et al.
Clin Genitourin Cancer
. 2018 Dec;
17(2):e356-e359.
PMID: 30558835
No abstract available.
10.
Farolfi A, Ceci F, Graziani T, Lambertini A, Cervati V, Basilico G, et al.
Clin Genitourin Cancer
. 2018 Mar;
16(3):e497-e499.
PMID: 29550202
No abstract available.